According to Coherent Market Insights (CMI), the global sickle cell disease treatment market size is expected to expand from USD 3.20 Bn in 2025 to USD 8.81 Bn by 2032, recording a CAGR of 15.6% ...

CMS has reached agreements with drug manufacturers to provide gene therapies to treat sickle cell disease to Medicaid recipients under a new outcomes-based model. A total of 33 states, including the ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...